Advertisement
UK markets closed
  • NIKKEI 225

    38,385.73
    +29.67 (+0.08%)
     
  • HANG SENG

    19,073.71
    -41.35 (-0.22%)
     
  • CRUDE OIL

    78.73
    +0.71 (+0.91%)
     
  • GOLD FUTURES

    2,391.70
    +31.80 (+1.35%)
     
  • DOW

    39,827.27
    +269.16 (+0.68%)
     
  • Bitcoin GBP

    51,688.63
    +3,279.62 (+6.77%)
     
  • CMC Crypto 200

    1,377.75
    +109.81 (+8.66%)
     
  • NASDAQ Composite

    16,726.15
    +214.97 (+1.30%)
     
  • UK FTSE All Share

    4,596.71
    +13.48 (+0.29%)
     

Exploring Analyst Estimates for Ventas (VTR) Q1 Earnings, Beyond Revenue and EPS

Analysts on Wall Street project that Ventas (VTR) will announce quarterly earnings of $0.75 per share in its forthcoming report, representing an increase of 1.4% year over year. Revenues are projected to reach $1.16 billion, increasing 8.1% from the same quarter last year.

Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.

Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.

While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.

ADVERTISEMENT

With that in mind, let's delve into the average projections of some Ventas metrics that are commonly tracked and projected by analysts on Wall Street.

Analysts' assessment points toward 'Revenues- Resident fees and services' reaching $784.47 million. The estimate suggests a change of +11.3% year over year.

Analysts forecast 'Revenues- Income from loans and investments' to reach $2.62 million. The estimate suggests a change of -80.7% year over year.

Based on the collective assessment of analysts, 'Revenues- Rental income- Outpatient medical & research portfolio' should arrive at $221.52 million. The estimate points to a change of +9.1% from the year-ago quarter.

The collective assessment of analysts points to an estimated 'Depreciation and amortization' of $363.52 million. Compared to the current estimate, the company reported $282.12 million in the same quarter of the previous year.

View all Key Company Metrics for Ventas here>>>

Shares of Ventas have demonstrated returns of +4.2% over the past month compared to the Zacks S&P 500 composite's -2.5% change. With a Zacks Rank #4 (Sell), VTR is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Ventas, Inc. (VTR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research